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Abstract. 
 
Impaired biosynthetic processing of the cys-
 
tic ﬁbrosis (CF) transmembrane conductance regulator
(CFTR), a cAMP-regulated chloride channel, consti-
tutes the most common cause of CF. Recently, we have
identiﬁed a distinct category of mutation, caused by pre-
mature stop codons and frameshift mutations, which
manifests in diminished expression of COOH-termi-
nally truncated CFTR at the cell surface. Although the
biosynthetic processing and plasma membrane targeting
of truncated CFTRs are preserved, the turnover of the
complex-glycosylated mutant is sixfold faster than its
wild-type (wt) counterpart. Destabilization of the trun-
cated CFTR coincides with its enhanced susceptibility
to proteasome-dependent degradation from post-Golgi
compartments globally, and the plasma membrane spe-
ciﬁcally, determined by pulse–chase analysis in conjunc-
tion with cell surface biotinylation. Proteolytic cleavage
of the full-length complex-glycosylated wt and degrada-
tion intermediates derived from both T70 and wt CFTR
requires endolysosomal proteases. The enhanced pro-
tease sensitivity in vitro and the decreased thermostabil-
ity of the complex-glycosylated T70 CFTR in vivo sug-
gest that structural destabilization may account for the
increased proteasome susceptibility and the short resi-
dence time at the cell surface. These in turn are respon-
sible, at least in part, for the phenotypic manifestation of
CF. We propose that the proteasome-ubiquitin pathway
may be involved in the peripheral quality control of
other, partially unfolded membrane proteins as well.
Key words: cystic ﬁbrosis • lysosomal proteolysis •
structural destabilization • functional complementation
• ubiquitination
 
Introduction
 
Newly synthesized secretory and membrane proteins must
attain their native conformation spontaneously or with the
assistance of ER-resident and cytosolic chaperones before
their export from the ER. The ER quality control mecha-
 
nism assures that functionally incompetent, misfolded,
or unassembled oligomeric proteins are retained and tar-
geted for proteolysis via the ER-associated degradation
 
(ERAD)
 
1
 
 pathway (Hurtley and Helnius, 1989; Brodsky
and McCracken, 1997; Bonifacino and Weismann, 1998;
Ellgaard et al., 1999; Wickner et al., 1999). The ERAD in-
volves the recognition, dislocation, and proteolysis of mis-
folded polypeptides by the 26S proteasome, a multicatalytic
enzyme complex localized to the cytoplasm and nucleus
(Baumeister et al., 1998; Bonifacino and Weismann, 1998;
Brodsky and McCracken, 1999; Plemper and Wolf, 1999).
The ATP-dependent cleavage process is facilitated by mul-
 
tiple ubiquitin attachments to the 
 
 
 
-amino groups of lysine
residues of the substrate and catalyzed by a cascade of en-
 
zymatic reactions involving ubiquitin-activating (E1) and
-conjugating (E2) enzymes in addition to ubiquitin-protein
ligases (E3) (Hershko and Ciechanover, 1998).
Trafficking defects have been recognized as the underly-
ing mechanism in a growing number of genetic diseases,
 
including cystic fibrosis (CF), diabetes insipidus, and 
 
 
 
1
 
antitrypsin deficiency (Thomas et al., 1995; Bonifacino and
Weismann, 1998; Hershko and Ciechanover, 1998; Aridor
and Balch, 1999; Kopito, 1999; Schwartz and Ciechanover,
1999). CF, the most prevalent recessive genetic disorder in
the caucasian population, is caused by the dysfunction of
the CF transmembrane conductance regulator (CFTR), a
member of the ATP-binding cassette transport protein
family (Riordan et al., 1989; Rommens et al., 1989). CFTR
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is a cAMP-stimulated Cl
 
 
 
 channel, residing predominantly
at the cell surface and, less abundantly, in the endosomal
compartment (Bradbury, 1999). The channel consists of
two homologous halves, each comprised of six transmem-
brane helices and a nucleotide binding domain (NBD1
and NBD2), which are connected by the regulatory do-
main (Riordan et al., 1989). This complex, multidomain
structure conceivably renders the posttranslational folding
of wild-type (wt) CFTR inefficient. Approximately 70% of
the newly synthesized wt CFTR is trapped in the ER as
core-glycosylated folding intermediate (apparent molecu-
lar weight 
 
 
 
150, 000) and degraded with a 
 
t
 
1/2 
 
of 
 
 
 
30 min
by the ERAD. Proteasome activity is responsible, at least
in part, for the degradation of the co- and posttranslation-
ally ubiquitinated and incompletely folded CFTR at the
ER (Jensen et al., 1995; Ward et al., 1995; Xiong et al.,
1999). However, inhibition of proteasomes has failed to
promote the processing of core-glycosylated wt as well as
the 
 
 
 
F508 CFTR (Jensen et al., 1995; Ward et al., 1995).
Only 20–30% of the newly synthesized CFTR enters the
secretory pathway after its ATP-dependent conforma-
tional maturation (Lukacs et al., 1994; Zhang et al., 1998)
assisted by cytosolic and ER-resident chaperones (Yang et
al., 1993; Pind et al., 1994; Loo et al., 1998; Meacham et al.,
1999). Processing of the high mannose type N-linked gly-
can to complex type oligosaccharides in the cis/medial
Golgi region is reflected by a decreased electrophoretic
mobility (
 
 
 
180 kD), providing a convenient method to
monitor the trafficking of the CFTR (Cheng et al., 1990;
Lukacs et al., 1994; Ward and Kopito, 1994; Riordan,
1999). Not only does the folded complex-glycosylated
CFTR have a slow turnover in vivo (
 
t
 
1/2
 
 
 
  
 
12 h), but it also
displays a conformation which is more resistant to proteol-
ysis in vitro (Zhang et al., 1998). The posttranslational
folding or conformational maturation of CFTR is indepen-
dent of ER to Golgi vesicular transport, implying that
complex glycosylation is not a prerequisite to attain the
native conformation (Lukacs et al., 1994; Ward and Ko-
pito, 1994; Zhang et al., 1998).
The majority of CF-associated point mutations, including
the most common, 
 
 
 
F508 CFTR, impair biosynthetic pro-
cessing by disrupting posttranslational folding at the ER
(Welsh and Smith, 1993; Zielenski and Tsui, 1995; Riordan,
1999). Recently, we have identified a mechanistically dis-
tinct category of mutation, caused by premature termina-
tions and frameshift mutations in the CF gene (Haardt et
al., 1999). Although the ER processing of these COOH-
terminally truncated CFTR variants missing their last 70–
82 amino acid residues (T70 and T82 CFTR) is similar to
that of the wt form, the biological half-life of the complex-
glycosylated mutants is sixfold shorter than their wt coun-
terpart (Haardt et al., 1999). Although the proteolytic elim-
ination mechanism of the processing mutants entrapped in
the ER has been extensively studied (Welsh and Smith,
1993; Kopito, 1999; Riordan, 1999), the cellular processes
responsible for the short residence time of the truncated
CFTR in post-Golgi compartments remained obscure.
Here we show that deletion of the COOH terminus ren-
ders the complex-glycosylated truncated CFTR highly sus-
ceptible to proteasome-dependent proteolysis at post-
Golgi compartments, including the plasma membrane.
Structural destabilization, demonstrated by increased pro-
 
tease susceptibility in vitro and diminished thermostability
of the complex-glycosylated mutants in vivo, may serve as
signal for premature proteolysis. In contrast, lysosomal
proteolysis appears to represent the rate-limiting step in
the degradation of the complex-glycosylated wt CFTR.
These results reveal a novel aspect of the proteasome-
dependent degradation pathway in the elimination of non-
native CFTR after its escape from the ER quality control.
 
Materials and Methods
 
Plasmids
 
The influenza hemagglutinin (HA) epitope was attached to the NH
 
2 
 
ter-
minus ubiquitin using PCR mutagenesis and the cDNA of the yeast ubiq-
uitin as template (provided by Dr. R. Haguenauer-Tsapis, Jacques
Monod, University of Paris VII, Paris, France). To generate the Tac-
Lamp1 chimera, the extracellular and transmembrane segment of the in-
terleukin 2 receptor (Tac) was fused to the cytoplasmic tail of Lamp-1.
The constructs were sequenced to verify that no errors had been intro-
duced. The cDNA, encoding for the Tac and Tac-TCR
 
 
 
, were provided
by Dr. J. Bonifacino (National Institutes of Health, Bethesda, MD). Tac,
Tac-TCR
 
 
 
, and Tac-Lamp1 were stably transfected in BHK-21 cells using
the pNUT expression cassette (Haardt et al., 1999).
 
Cell Lines and Transfections
 
Mixtures of stably transfected BHK-21 cells expressing wt, truncated
CFTR (missing the last 26, 70, 82, and 98 amino acid residues: T26, T70,
T82, and T98 CFTR, respectively) or Tac, Tac-TCR
 
 
 
, and Tac-Lamp1,
were generated and maintained as described (Haardt et al., 1999). Intesti-
nal epithelia (T84 and CaCo-2) expressing endogenous CFTR were cul-
tured as described (Lukacs et al., 1993, 1994). COS-1 cells were transiently
transfected with Lipofectamine (Haardt et al., 1999).
 
Electrophoresis and Immunoblotting
 
Cells were washed with ice-cold PBS and lysed in RIPA buffer (150 mM
NaCl, 20 mM Tris-HCl, 1% Triton X-100, 0.1% SDS, and 0.5% sodium
deoxycholate, pH 8.0), containing 5 
 
 
 
g/ml of leupeptin and pepstatin A,
10 mM iodoacetamide, and 1 mM PMSF at 4
 
 
 
C. Nuclei and unbroken cells
were removed by centrifugation (15,000 
 
g
 
,
 
 
 
15 min at 4
 
 
 
C). Proteins were
denatured in Laemmli sample buffer, separated by SDS-PAGE, and
transferred to nitrocellulose membrane. Immunoblotting was performed
as described previously, using mouse monoclonal L12B4 and M3A7 anti-
CFTR antibodies (Abs; Kartner et al., 1992), mouse monoclonal anti-HA
(Covance), and antiubiquitin Abs (Santa Cruz Biotechnology, Inc.;
Lukacs et al., 1994). Primary Abs were visualized by horseradish peroxi-
dase–conjugated sheep anti–mouse IgG and enhanced chemilumines-
cence (ECL Western blot kit; Amersham Pharmacia Biotech).
 
Metabolic Pulse–Chase Labeling 
and Immunoprecipitation
 
BHK or COS-1 cells were pulse labeled in the presence of [
 
35
 
S]methionine
and [
 
35
 
S]cysteine (0.1–0.25 mCi/ml; Amersham Pharmacia Biotech) and
chased in complete medium for the specified time at 37
 
 
 
C. CFTR was im-
munoprecipitated with a mixture of M3A7 and L12B4 anti-CFTR Abs, as
described (Lukacs et al., 1994). The duration of pulse and chase periods
and withdrawals of samples are indicated on schematic figures. Radioac-
tivity associated with CFTR was visualized by fluorography and quanti-
fied by PhosphorImager (PDI) using the ImageQuant software (Haardt et
al., 1999).
 
Cell Surface Biotinylation
 
To determine the expression levels of wt and truncated CFTR at the cell
surface and early endosome, BHK cells were metabolically labeled to
steady state overnight and rinsed with H buffer (154 mM NaCl, 10 mM
Hepes, 3 mM KCl, 1 mM MgCl
 
2
 
, 0.1 mM CaCl
 
2
 
, 10 mM glucose, pH 7.6).
Cells were biotinylated in the presence of 1 mg/ml sulphosuccinimidyl-
2-(biotinamido)ethyl-1,3-dithiopropionate (EZ-Link sulfo-NHS-SS-biotin;
Pierce Chemical Co.) in H buffer at 37
 
 
 
C (Lukacs et al., 1997). Cells were 
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washed with ice-cold PBS, supplemented with 0.1% BSA, 1 mM MgCl
 
2
 
,
and 0.1 mM CaCl
 
2
 
, and solubilized in RIPA buffer. Biotinylated CFTR
was isolated by immunoprecipitation with M3A7 and L12B4 anti-CFTR
Abs and then on Streptavidin-Sepharose (Sigma-Aldrich). Biotinylated
CFTR was visualized with fluorography and its radioactivity was mea-
sured by PhosphorImage analysis.
 
Subcellular Fractionation
 
Cells were washed with ice-cold PBS three times, resuspended in homoge-
nization medium (0.25 M sucrose, 10 mM Hepes, 1 mM EDTA, 1 mM
DTT, pH 7.2, supplemented with 5 
 
 
 
g/ml leupeptin, 5 
 
 
 
g/ml pepstatin A,
and 2 mM PMSF). CHO-BQ1, CHO-K1, CaCo-2, and T84 cells were ho-
mogenized by nitrogen cavitation as described (Zhang et al., 1998),
whereas BHK cells were homogenized in a Dounce homogenizer. After
the sedimentation of unbroken cells and nuclei (2,500 
 
g
 
, 5 min at 4
 
 
 
C), mi-
tochondria were pelleted by centrifugation (10,000 
 
g
 
, 10 min at 4
 
 
 
C) from
the postnuclear supernatant. Microsomes were fractionated on self-form-
ing Percoll density gradient (25% Percoll in 0.25 M sucrose, 10 mM Hepes
and 1 mM EDTA, 5 
 
 
 
g/ml leupeptin, 5 
 
 
 
g/ml pepstatin A, pH 7.3) at
28,000 
 
g 
 
for 100 min. The density profile of the gradient was verified with
density-marker beads (Sigma-Aldrich) and fractions were downloaded as
described (Lukacs et al., 1997). In some experiments lysosomes were la-
beled with the fluid-phase marker, fluorescein-dextran (0.5 mg/ml, 70 kD;
Molecular Probes), overnight and chased in full medium for 3 h. Alkaline
phosphatase, 
 
 
 
-glucoronidase, and mannosidase II activity, specific mark-
ers of plasma membrane, lysosomes, and Golgi regions, respectively, were
measured as described (Lukacs et al., 1994, 1997). The fluorescence asso-
ciated with the fractions was determined with fluorescence spectropho-
tometry in the presence of 0.2% Triton X-100.
 
Limited Proteolysis
 
BHK cells expressing wt or T70 CFTR were incubated in the presence of
cycloheximide (100 
 
 
 
g/ml) to ensure the degradation of the core-glycosy-
lated wt and T70 CFTR (Lukacs et al., 1994). Isolation of ER-, Golgi com-
plex–, and plasma membrane–enriched microsomes was performed as de-
scribed (Zhang et al., 1998). The microsomes (0.8–1.5 mg/ml) were
digested in HSE medium (10 mM Hepes, 0.25 M sucrose, pH 7.6) in the
presence, at the indicated concentration, of trypsin or proteinase K for 15
min at 4
 
 
 
C (Zhang et al., 1998). Proteolysis was terminated by the addition
of 1 mM PMSF. Samples were immediately denatured in 2
 
 
 
 Laemmli
sample buffer at 37
 
 
 
C for 20 min and probed by immunoblot analysis.
 
Measurement of the cAMP-stimulated Iodide 
Conductance of the Plasma Membrane
 
The plasma membrane cAMP-dependent halide conductance of BHK
cells expressing T70 CFTR was determined with iodide efflux as described
(Mohamed et al., 1997). Iodide efflux was initiated by replacing the load-
ing buffer with efflux medium (composed of 136 mM nitrate in place of io-
dide). The extracellular medium was replaced every minute with efflux
buffer (1 ml). After a steady state was reached, the intracellular cAMP
level was raised by agonists (10 
 
 
 
M forskolin, 0.2 mM CTP-cAMP, and 0.2
mM isobutyl-methyl xanthane) to achieve maximal phosphorylation of
the T70 CFTR. The collection of the efflux medium resumed for an addi-
tional 6–9 min. The amount of iodide in each sample was determined with
an iodide-selective electrode (Orion).
 
Results
 
Cell Surface Delivery of the Truncated 
CFTR Is Preserved
 
We have demonstrated previously that the steady state ex-
pression level of the complex-glycosylated CFTR missing
its last 70, 82, or 98 amino acids (designated as T70, T82,
and T98 CFTR) was decreased by 
 
 
 
90% compared with
wt CFTR in heterologous expression systems (Haardt et
al., 1999). In contrast, deletion of the last 26 amino acid
residues (T26 CFTR) was without effect (Mickle et al.,
1998; Haardt et al., 1999). It was also shown that neither
 
the translational rate nor the biosynthetic maturation of
the T70 and T82 CFTR was significantly impaired at the
ER in transient COS-1 (Haardt et al., 1999) or in stable
BHK expression systems (Benharouga, M., and G.L.
Lukacs, unpublished data). We proposed that, in contrast
to the most prevalent CF-associated processing mutations
(e.g., 
 
 
 
F508 CFTR), which compromise the biogenesis of
CFTR, destabilization of the mature form at distal stages
of the biosynthetic or endocytic pathway accounts for the
phenotypic manifestation of truncated CFTR (Haardt et
al., 1999).
To examine whether impaired plasma membrane target-
ing of the complex-glycosylated truncated CFTR can at-
tribute to accelerated degradation, the efficacy of cell surface
delivery of the mutant was determined first. BHK cells con-
stitutively expressing wt or truncated CFTR were metaboli-
cally labeled with [
 
35
 
S]methionine and [
 
35
 
S]cysteine over-
night and cell surface–exposed CFTR was covalently tagged
with sulfo-NHS-SS-biotin. After the solubilization and
immunoprecipitation of CFTR, biotinylated polypeptides
were isolated on Streptavidin-Sepharose and visualized by
fluorography after separation by SDS-PAGE (Fig. 1 A).
PhosphorImage analysis revealed that the abundance of bio-
tinylated T70, T82, and T98 CFTR was only 5–8% relative to
wt or T26 CFTR in the mixture of clones (Fig. 1 B). The
steady state level of the complex-glycosylated T70, T82, and
T98 CFTR pool was also diminished to 5–10% relative to
that of wt or T26 CFTR, as determined by quantitative West-
ern blotting using L12B4 or M3A7 anti-CFTR Abs (Fig. 1, B
and C). The complex and core-glycosylated forms of wt and
truncated CFTR could be distinguished by their distinct elec-
trophoretic mobility as well as their endoglycosidase H sensi-
tivity as described previously and shown on Fig. 1, C and D
(Cheng et al., 1990). The parallel decrease in the size of the
complex-glycosylated and biotinylated pools of the truncated
CFTR suggests that the plasma membrane targeting is
largely preserved. To confirm this notion, the cell surface de-
livery of newly synthesized T70 CFTR was measured.
Wt and T70 CFTR were pulse labeled for 15 min and
those molecules that arrived at the cell surface were bio-
tinylated during a 1-h chase. Biotinylated CFTR was affin-
ity isolated and visualized by fluorography (Fig. 1 E, biot).
Radioactivity of biotinylated forms was quantified with
PhosphorImage analysis and expressed as a percentage of
the respective pulse-labeled core-glycosylated CFTR (Fig.
1 E, lysate). The cell surface targeting efficiency of T70
CFTR was 74 
 
 
 
 4% (mean 
 
 
 
 SEM, 
 
n
 
 
 
  
 
4) of wt CFTR.
Since this measurement is compounded by the rapid degra-
dation of the complex-glycosylated T70 CFTR (
 
t
 
1/2 
 
  
 
1.5–2 h,
see also Fig. 6 B; Haardt et al., 1999), the calculated target-
ing efficiency of the T70 CFTR represents an underesti-
mate and suggests that the plasma membrane delivery of
the complex-glycosylated T70 CFTR is largely preserved.
 
Contribution of Endolysosomal Proteases to the Turnover 
of Complex-glycosylated Wt and Truncated CFTR
 
In light of efficient clathrin-dependent internalization of
CFTR (Prince et al., 1994, 1999; Lukacs et al., 1997; Brad-
bury, 1999) and proteolysis of other plasma membrane-resi-
dent ATP-binding cassette transporters in the vacuolar/lyso-
somal compartments (Loayza and Michaelis, 1998; Hicke, 
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1999; Katzmann et al., 1999), we hypothesized that COOH-
terminal truncations may interfere with the recycling of
CFTR and lead to premature endolysosomal proteolysis.
To test this hypothesis, the disposal rate of the metabol-
ically labeled, complex-glycosylated T70 and T82 CFTR
was measured in the presence of lysosomal protease inhib-
itors after allowing the conversion of the core- into com-
plex-glycosylated form (Fig. 2 A). The degradation rate
was unaltered upon exposing the cells to NH
 
4
 
Cl, chloro-
quin, or bafilomycin B, agents that inhibit endolysosomal
proteolysis by dissipating the acidic luminal pH and inter-
fering with cargo delivery (Fig. 2 B). Similarly, leupeptin
and pepstatin A, inhibitors of cathepsins B, H, L, N, S, and
T (Seglen, 1983), have a negligible effect on the degrada-
tion rate (Fig. 2, A and B) and the steady state expression
of truncated CFTRs (Fig. 2 C). In contrast, these drugs sta-
bilized the interleukin 2 receptor 
 
 
 
 chain (Tac), which is
targeted for lysosomal degradation (Fig. 2 D; Hemar et al.,
1995), validating their efficacy and suggesting that the ini-
tial proteolysis of the truncated CFTR is largely indepen-
dent of endolysosomal proteases.
Pulse–chase analysis has revealed that the disposal of the
complex-glycosylated wt CFTR was mitigated by NH
 
4
 
Cl
 
and chloroquin (Fig. 2, E and F). To further examine the
discordant role of lysosomal proteases in the wt and T70
CFTR degradation, subcellular fractionation was per-
formed, after the enrichment of short-lived proteolytic in-
termediates that may have been difficult to detect by treat-
ing the cells with the cathepsin inhibitors. Heavy and light
microsomes, containing predominantly lysosomes and Golgi
complex plasma membrane, and endosomes, respectively,
were isolated on Percoll density gradient (Fig. 3 A).
Although cathepsin inhibitors stabilized the complex-
glycosylated wt CFTR by 7–10-fold in lysosomes as well as
in the light-density fraction, only a modest accumulation of
T70 CFTR could be documented by immunoblot analysis
(Fig. 3 B). Similar results were obtained in lysosomes iso-
lated by the calcium-precipitation method (data not shown;
Kawashima et al., 1998). Surprisingly, leupeptin and pep-
statin A provoked the accumulation of degradation inter-
mediates of both wt and T70 CFTR predominantly in lyso-
somes (Fig. 3 B). These inhibitors also provoked the
appearance of breakdown products in isolated lysosomes
of intestinal epithelia (CaCo-2 and T84) expressing CFTR
endogenously, implying that lysosomal proteolysis cannot
be attributed to heterologous overexpession (data not
Figure 1. Steady state ex-
pression and cell surface tar-
geting of wt and truncated
CFTR. (A) Expression level
of biotinylated CFTR. An
identical number of BHK-21
cells expressing wt, T26, T70,
T82, or T98 CFTR were met-
abolically labeled overnight
with [35S]methionine and
[35S]cysteine. Plasma mem-
brane proteins biotinylated
with 1 mg/ml sulfo-NHS-SS-
biotin for 60 min at 37 C
were isolated by immunopre-
cipitation with L12B4 and
M3A7 anti-CFTR Abs and
then on Streptavidin-
Sepharose (top). 10% of the
immunoprecipitate was di-
rectly loaded (bottom). To
avoid clonal variations, this,
and the experiments shown in
C, were carried out on a mix-
ture of clones. The sulfo-
NHS-SS-biotin remains mem-
brane impermeant during the labeling, indicated by the lack of biotinylated core-glycosylated forms. Complex- and core-glycosylated
CFTR are indicated by black and white arrowheads, respectively. (B) The expression level of wt and truncated CFTR at the cell surface
(biotinylated) and at post-ER compartments (complex glycosylated). The radioactivity of biotinylated CFTR was measured by Phos-
phorImage analysis in experiments as described in the legend to A. The level of the complex-glycosylated CFTR was determined by
densitometry of immunoblots (C). Data represent means   SEM (n   3), and are expressed as the percentage of the wt, designated as
100%. (C) Expression of wt, T26, T70, T82, and T98 CFTR in BHK-21 cells. CFTR expression in cell lysate was assessed by immuno-
blotting using the L12B4 and M3A7 anti-CFTR Abs. BHK lane contains a lysate of the parental cells. (D) Glycosidase sensitivity of com-
plex- and core-glycosylated wt and T70 CFTR. Cell lysates were incubated in the presence or absence of endoglycosidase H (endo H) or
peptide-N-glycosidase F (PNGase F) for 3 h at 37 C. Polypeptides were separated by SDS-PAGE and probed by the L12B4 anti-CFTR
Ab. Complex-, core-, and deglycosylated CFTR are indicated by black, white, and hatched arrowheads, respectively. (E) Targeting effi-
ciency of newly synthesized CFTR to the cell surface. After the pulse labeling of wt or T70 CFTR for 20 min, plasma membrane insertion
of the channels was determined by biotinylation during a 1-h chase at 37 C using freshly dissolved sulfo-NHS-SS-biotin (1 mg/ml) every 15
min. Biotinylated CFTR was precipitated with L12B4 and M3A7 Abs and then isolated on Streptavidin-Sepharose (biot). Labeled CFTR
was visualized by fluorography. To monitor the pulse labeling of total CFTR pools, 10% of the precipitate was loaded directly (lysate). 
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shown). Considering that cathepsin inhibitors are unable to
promote the ER processing of the core-glycosylated form
(Lukacs et al., 1994; Ward and Kopito, 1994), our results
suggest that endolysosomal proteases are essential for the
elimination of the complex-glycosylated full-length wt
CFTR. In addition, endolysosomal proteases appear to be
involved in the processing of the proteolytic intermediates
derived from both T70 and wt CFTR.
 
Proteasome-dependent Degradation of the
Complex-glycosylated Truncated CFTR
 
The 26S proteasome is responsible for the degradation of
misfolded polypeptides recognized by the ER quality con-
trol, short-lived cytosolic, and some plasma membrane
proteins after their ligand-induced internalization (Hoch-
strasser, 1996; Bonifacino and Weismann, 1998; Hershko
and Ciechanover, 1998; Brodsky and McCracken, 1999;
Plemper and Wolf, 1999; Schwartz and Ciechanover,
1999). To reveal the involvement of the 26S proteasome in
the metabolism of the truncated CFTR, the impact of the
peptide aldehyde, MG 132 (CBZ-leu-leu-leucinal), and
lactacystin, a specific, irreversible inhibitor of the 20S sub-
unit, was assessed (Fenteany et al., 1995).
The disappearance of the complex-glycosylated, but not
the core-glycosylated, T70, T82, and T98 CFTR was inhib-
ited 2.3-, 2.6-, and 2.1-fold, respectively, by lactacystin
when the drug was present during the pulse labeling and
chase (Figs. 4, A and B, and 5 A). MG132 exerted a less
pronounced effect (Fig. 4 B). Comparable inhibition was
Figure 2. The role of lyso-
somal proteases in the me-
tabolism of truncated and wt
CFTR. (A) After the pulse
labeling of T70, T82, and T98
CFTR expressors, BHK cells
were chased for 2 h to ensure
the conversion of core-glyco-
sylated form to complex-gly-
cosylated CFTR at 37 C.
Subsequent chase was per-
formed in the presence of
NH4Cl (15 mM). Bafilomycin
B (Baf B; 2  M) and leu-
peptin plus pepstatin A
(leu pep; 50  g/ml) were
present during the entire
pulse–chase. CFTR was im-
munoprecipitated and visual-
ized by fluorography. (B)
The radioactivity remaining
in the complex-glycosylated
T70, T82, and T98 CFTR af-
ter the chase was quantified
by PhosphorImage analysis
in experiments shown in A
and expressed as the percent-
age of the initial amount
present after 2 h of chase.
Data represent means  
SEM, n   3. (C) The effect of
chathepsin inhibitors on the
expression level of truncated
CFTR. BHK transfectants
were incubated with or with-
out leupeptin and pepstatin
A (50  g/ml) for 4 h. Equal
amounts of protein were
probed by immunoblotting as
described in the legend to
Fig. 1 C. (D) The metabolic
stability of Tac in BHK cells.
The turnover of Tac was de-
termined in the presence or
absence of leupeptin and
pepstatin A (50  g/ml). Metabolically labeled cells were chased for the indicated time, and Tac was isolated by immunoprecipitation
and visualized by fluorography. (E and F) Metabolic stability of the complex-glycosylated wt CFTR was determined in stably trans-
fected CHO cells in the presence of NH4Cl (15 mM), chloroquin (200  M), or leupeptin plus pepstatin A (leu pep; 50  g/ml) as de-
scribed for A and B. Statistical analysis was performed on samples subjected to a 20-h chase (F). Data are means   SEM, n   3. 
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observed when lactacystin was added after the pulse label-
ing (Fig. 4 C) or after a 2-h chase (Fig. 4 D). This latter
protocol has ensured that augmented conversion of the
core- to the complex-glycosylated form was not attribut-
able to the lactacystin effect. Similarly, preventing ER to
Golgi complex transport of the residual core-glycosylated
T70 CFTR with brefeldin A (BFA) failed to influence the
inhibitory effect of lactacystin (Fig. 4 D), substantiating
the notion that disposal of the complex-glycosylated mu-
tants is delayed, rather than that the escape of core-glyco-
sylated form is facilitated, by lactacystin. In fact, neither
lactacystin nor MG 132 promoted the processing of the
core-glycosylated T70 CFTR (Fig. 5 A), similarly to other
CFTR mutations identified in NBD1 (Jensen et al., 1995;
Van Oene et al., 2000). The maturation efficiency of T70
CFTR (20 
 
 
 
 2%, 
 
n
 
 
 
 
 
 9) was negligibly increased in the
presence of lactacystin (23 
 
 
 
 4%, 
 
n
 
 
 
 
 
 4).
If deletion of the COOH terminus destabilizes CFTR ex-
clusively in post-Golgi compartments, retention of folded
T70 CFTR in the ER would protect against degradation.
Taking advantage of the fact that BFA can provoke the ac-
cumulation of folded CFTR in the ER without interfering
with ERAD, the stability of folded T70 CFTR was mea-
sured after the elimination of the immature core-glycosy-
lated form (Fig. 4 E). The turnover of the folded core-gly-
cosylated T70 CFTR was fourfold slower (
 
t
 
1/2 
 
  
 
7 h)
 
 
 
than
that of the complex-glycosylated T70 CFTR (
 
t
 
1/2
 
 
 
  
 
1.8 h;
Fig. 4 F). In contrast, ER retention only marginally in-
creased the half-life of the wt CFTR (
 
t
 
1/2
 
 
 
  
 
14 h vs.  11 h;
Fig. 4 G), underlining our previous observations that desta-
bilization of T70 CFTR primarily manifests at the distal
stage of the secretory pathway. Similar stabilization was ob-
served upon retaining the complex-glycosylated T70 CFTR
in the distal Golgi region by aluminum fluoride (Ben-
harouga, M., and G.L. Lukacs, unpublished observation).
To rule out that cross talks between lysosomal and pro-
teasomal degradation pathway account for the stabiliza-
tion of the complex-glycosylated T70 CFTR, the specific-
ity of the drugs was examined on BHK cells expressing
Tac-TCR  or Tac-Lamp1 chimeras. Although the former
polypeptide is a substrate of the ERAD (Bonifacino et al.,
1990), the latter is targeted for lysosomal proteolysis
(Marks et al., 1996). As we anticipated, proteasome inhibi-
tors mitigated the disappearance of Tac-TCR , but not
Tac-Lamp1, whereas bafilomycin B, but not the protea-
some inhibitors, stabilized Tac-Lamp1 (Fig. 5, B and C).
Consistent with the notion that proteasome activity ac-
counts, at least in part, for the proteolysis of the complex-
glycosylated truncated CFTR, proteasome inhibitors in-
creased the steady state level of the complex-glycosylated
T70, T82, and T98 CFTR by two- to fourfold according to
densitometric analysis of immunoblots (Fig. 5 D). This was
also reflected by the elevated cAMP-activated anion con-
ductance of the plasma membrane (Fig. 5 E). Lactacys-
tin treatment significantly increased the protein kinase
A–stimulated iodide release from BHK cells constitutively
expressing T70 CFTR as compared with nontreated cells
(Fig. 5 E).
Proteasome-dependent Turnover of Cell 
Surface Resident T70 CFTR
To investigate the influence of proteasome inhibitors on
the residence time of truncated CFTR at the cell surface,
the turnover of biotinylated T70 CFTR was measured by
the pulse–chase technique. The half-life of biotinylated
T70 CFTR is sevenfold shorter (t1/2   1.9 h) than the wt
CFTR (t1/2   14.5 h; Fig. 6, A and B). Lactacystin and
MG132 inhibited the turnover of biotinylated T70 CFTR
by 2.6- and 1.9-fold, respectively. This observation pro-
vides direct support for our hypothesis that proteasomes,
Figure 3. The effect of leu-
peptin and pepstatin A on
the metabolism of wt and
T70 CFTR in lysosomes. (A)
Separation of subcellular or-
ganelles on Percoll density
gradient. Postnuclear super-
natants of wt- and T70
CFTR–expressing BHK cells
were fractionated on a 25%
Percoll density gradient as
described in Materials and
Methods. Organellar distri-
bution was established by the
activity of specific marker
enzymes (plasma mem-
brane, alkaline phosphatase
[A P]; Golgi, mannosidase II
[Mann II]; and lysosomes,
 -glucuronidase [ -gluc]) as
described previously (Lukacs
et al., 1997). Enrichment of
lysosomes in the high density fractions was confirmed by the accumulation of fluorescein-dextran (70 kD, 1.5 mg/ml) as well after an
overnight labeling and a 3-h chase. (B) BHK cells expressing wt or T70 CFTR were treated with leupeptin and pepstatin A overnight
(50  g/ml) and for 4 h (100  g/ml), respectively. Microsomes were isolated on Percoll density gradient, and fractions 5–13 and 15–18,
comprising the majority of lysosomes and plasma membrane, Golgi regions, and endosomes, respectively, were pooled. Equal amounts
(50  g) of protein were loaded and probed with NBD1 (L12B4) and NBD2 (M3A7) specific anti-CFTR Abs using ECL.Benharouga et al. Peripheral Quality Control of CFTR 963
directly or indirectly, are involved in the proteolysis of
complex-glycosylated T70 CFTR from the cell surface and
endosomal compartments (Fig. 6, C and D).
Ubiquitination of the Complex-glycosylated T70 CFTR
Since recognition of most of the substrates destined for de-
struction by the proteasome requires polyubiquitin modi-
fication (Hershko and Ciechanover, 1998; Laney and
Hochstrasser, 1999; Plemper and Wolf, 1999; Hirsh and
Ploegh, 2000), we examined whether T70 CFTR is sub-
jected to ubiquitin attachments. COS-1 cells were tran-
siently cotransfected with plasmids encoding for the wt or
T70 CFTR and HA-tagged ubiquitin (HA-Ub). HA-Ub
was detected with the monoclonal anti-HA Ab in immu-
noprecipitated T70 CFTR. The abundance of high molec-
ular weight immunoreactive polypeptides was augmented
by lactacystin and MG132, suggesting that proteasome ac-
tivity is involved in the degradation of polyubiquitinated
Figure 4. Biochemical res-
cue of the complex-glycosy-
lated form of truncated
CFTR. (A and B) The com-
plex-glycosylated truncated
CFTR is stabilized by protea-
some inhibitors. BHK cells
expressing T70, T82, and T98
CFTR were metabolically la-
beled and chased in the pres-
ence of lactacystin (Lac; 10
 M) or MG132 (MG; 10
 M). The stability of the com-
plex-glycosylated form was
monitored by immunoprecipi-
tation and fluorography. The
radioactivity remaining in the
complex-glycosylated CFTR
was measured by Phosphor-
Image analysis and expressed
as the percentage of the
amount after a 2-h chase (B).
Data are means   SEM, n  
3–4. (C and D) To rule out
that lactacystin (10  M) de-
lays the degradation of the
complex-glycosylated form
by promoting the biosynthe-
sis or the conversion of the
core-glycosylated form, cells
were treated with lactacystin
after the pulse labeling (C)
or after the conversion of the
core- to complex-glycosy-
lated T70 (D). This protocol
provided similar inhibition
of the complex-glycosylated
turnover as reported for A.
When indicated, BFA (5  g/
ml) was included to prevent
the conversion of the resid-
ual core-glycosylated form (D and E). (E–G)
Comparison of the turnover rate of folded wt
and T70 CFTR in the ER and post-Golgi com-
partments. After the pulse labeling of BHK
transfectants, the fully mature core-glycosylated
T70 and wt CFTR were accumulated in the ER
by BFA (5  g/ml) during a 2-h chase. The disap-
pearance of the folded core-glycosylated form
was monitored during a subsequent 15-h chase in
the presence of BFA and was expressed as the
percentage of the amount detected after a 2-h
chase (F and G). The stability of the complex-
glycosylated T70 and wt CFTR, representing
post-Golgi pools, was determined as described
for A.The Journal of Cell Biology, Volume 153, 2001 964
T70 CFTR (Fig. 7 A, top, lanes 8–10). Similar results were
obtained by monitoring the conjugation of endogenous
Ub with a monoclonal anti-Ub Ab (Fig. 7 A, middle, lanes
6–10). Ubiquitinated T70 CFTR could not be detected in
cells expressing T70 CFTR or HA-Ub individually (Fig. 7
A, top, lanes 3–7) or after mock transfection (Fig. 7 A,
lanes 1–3), validating the specificity of the assay. To dis-
criminate whether polyubiquitinated T70 CFTR was de-
rived from the core- and/or the complex-glycosylated T70
CFTR (Jensen et al., 1995; Ward et al., 1995; Xiong et al.,
1999), double immunoprecipitation of metabolically la-
beled T70 CFTR was performed.
Stably transfected BHK cells were pulse labeled for 20
min and chased for 2 h to ensure the elimination of core-
glycosylated T70 CFTR, verified by fluorography (Fig. 7
B, bottom, lanes 1 and 2; see also Fig. 4 D). In a second
set of samples, separation of ubiquitinated adducts was
achieved by sequential immunoprecipitation with anti-
CFTR and then with anti-Ub Ab. The results show that a
negligible amount of polyubiquitinated and core-glycosy-
lated T70 CFTR persisted after the initial 2-h chase (Fig. 7
B, top and bottom, lanes 1 and 2). In contrast, radioactiv-
ity appeared in the high molecular weight, polyubiquiti-
nated T70 CFTR when MG132 was present during the last
2 h of chase (Fig. 7 B, top, lane 4). Accumulation of poly-
ubiquitinated T70 CFTR was more pronounced in COS-1
cells transiently coexpressing T70 CFTR and HA-Ub (Fig.
7 C). This is most likely due to the higher immunoprecipi-
tation efficiency of the anti-HA Ab. Ubiquitinated conju-
gates were not detectable upon inhibition of lysosomal
proteolysis, or in mock transfected cells (Fig. 7 B, top and
middle, and C). Considering that the turnover of the
complex-glycosylated, but not the core-glycosylated T70
CFTR, is sensitive to proteasome inhibitors and the core-
Figure 5. Functional rescue
of the T70 CFTR by lactacys-
tin is exerted by selective in-
hibition of proteasomes. (A)
Protease inhibitors have no
effect on the disposal and
maturation efficiency of the
core-glycosylated T70 CFTR.
Pulse-labeled (20 min) BHK
transfectants were chased in
the presence of lactacystin
(10   M), MG 132 (10  M),
or leupeptin and pepstatin A
(50  g/ml) as indicated. T70
CFTR was visualized by im-
munoprecipitation and fluo-
rography. PhosphorImage
analysis showed that none of
the drug had significantly de-
layed the degradation of the
core-glycosylated form (not
shown). (B) Lactacystin (10
 M), but not leupeptin and
pepstatin A (50  g/ml), im-
pedes the degradation of the
core-glycosylated Tac-TCR .
Stable transfectants were
pulse labeled for 15 min and
chased in the presence of the
indicated drugs. Fluorogra-
phy was performed as de-
scribed in the legend to Fig. 2
D. (C) The degradation of
the Tac-Lamp1 chimera is
sensitive to the inhibition of
the vacuolar H -ATPase
with bafilomycin B (Baf B).
BHK cells stably expressing
Tac-Lamp1 were labeled (30
min) and chased for 2 h. Af-
ter the addition of NH4Cl (10 mM), bafilomycin B (2  M), or MG132 (10  M) the cells were chased for an additional 3 h and Tac-Lamp1
was isolated by immunoprecipitation. (D) The effect of lactacystin and MG132 on the steady state expression of mutant CFTR. Equal
amounts of whole cell lysate, obtained from cells exposed to lactacystin (Lac; 10  M) and MG132 (10  M) for 3 h, were separated by
SDS-PAGE and immunoblotted with the L12B4 anti-CFTR Ab. Complex- and core-glycosylated CFTR are indicated by black and white
arrowheads, respectively. (E) Functional rescue of T70 CFTR by lactacystin. The cAMP-activated halide conductance of T70 CFTR–
expressing BHK cells was measured by the iodide efflux assay in the absence (control) or presence of lactacystin treatment ( Lac; 10  M
for 3 h). Data points are averages of triplicate determinations and show the difference of iodide release in the presence and absence of the
protein kinase A agonist cocktail (10  M forskolin, 0.5 mM dibutyryl-cAMP, and 0.2 mM IBMX), added as indicated.Benharouga et al. Peripheral Quality Control of CFTR 965
glycosylated form has been largely eliminated before pro-
teasome inhibition, we conclude that at least a fraction of
polyubiquitinated T70 CFTR originates from the com-
plex-glycosylated T70 CFTR. Although we cannot rule out
that a small amount of polyubiquitinated T70 CFTR is de-
rived from the core-glycosylated form, the following ob-
servations substantiate the notion that the complex-gly-
cosylated T70 CFTR can form ubiquitinated adducts.
Ubiquitinated complex-glycosylated form was visualized
by anti-Ub Abs after the separation of the core- and com-
plex-glycosylated forms by immunoprecipitation with anti-
CFTR Abs and wheat germ agglutinin affinity chromatog-
raphy (data not shown). Furthermore, coexpression of the
dominant negative K48RUb with T70 CFTR delayed the
disposal of the complex-glycosylated mutant CFTR (data
not shown).
Deletion of the COOH-terminal Tail 
Structurally Destabilizes CFTR
Nonnative or partially denatured soluble proteins are sub-
jected to ubiquitination and/or proteasome-mediated deg-
radation (Pacifici et al., 1993; Sadis et al., 1995; Michalek
et al., 1996; Gilon et al., 1998; Laney and Hochstrasser,
1999). A similar scenario may prevail for T70 CFTR if the
COOH-terminal tail is engaged in the structural stabiliza-
tion of CFTR in the post-ER compartment. A large body
of evidence demonstrates the existence of intra- and inter-
molecular interactions in CFTR (Seibert et al., 1996; Os-
tedgaard et al., 1997, 2000; Hall et al., 1998; Neville et al.,
1998; Zhang et al., 1998; Naren et al., 1999; Lu and Peder-
sen, 2000).
To compare the conformational stability of the com-
plex-glycosylated wt and T70 CFTR, in situ protease sus-
ceptibility and in vivo thermostability assays were per-
formed. The conformation of the cytosolic domains was
probed with limited proteolytic digestion in conjunction
with immunoblotting, a method we have implemented to
reveal conformational difference between the wt and the
 F508 CFTR (Zhang et al., 1998). Intact microsomes were
isolated by differential centrifugation from BHK cells, en-
riched in the complex-glycosylated wt or T70 CFTR by cy-
clohexamide chase, and subjected to limited proteolysis in
the presence of an increasing concentration of trypsin. Im-
munoblot analysis of the proteolytic fragments with the
L12B4 anti-CFTR Ab recognizing the NBD1 demon-
strates a distinct proteolytic digestion pattern and a mod-
erate, but reproducibly increased protease sensitivity of
the complex-glycosylated T70 CFTR compared with wt
CFTR (Fig. 8). Similar results were obtained with protein-
ase K and using the NBD2-specific, M3A7 anti-CFTR Ab
(data not shown), indicating that not only the NBD2, but
also the NBD1 conformation was altered upon truncating
the COOH terminus.
If the complex-glycosylated T70 CFTR was conforma-
tionally unstable, it was anticipated that the polypeptide in
vivo thermostability would be compromised. The temper-
ature dependence of the turnover of the complex-glycosy-
lated wt and T70 CFTR was compared by metabolic
pulse–chase studies. The turnover of the complex-glycosy-
lated T70 CFTR was more than fivefold faster at 40 C
(t1/2   0.5 h) than at 37 C (t1/2   2.7 h) (Fig. 9, A and C). In
sharp contrast, the turnover of the wt CFTR was only mar-
ginally affected at 40 C (t1/2   10.5 vs. 15 h at 37 C) (Fig. 9,
Figure 6. Residence time of
cell surface biotinylated wt
and T70 CFTR. (A) After
metabolic labeling of the
complex-glycosylated wt or
T70 CFTR, cell surface resi-
dent proteins were biotin-
ylated for 45 min and chased
for the indicated time in
complete medium. Biotin-
ylated CFTR was immuno-
precipitated by L12B4 and
M3A7 anti-CFTR Abs and
then isolated on Streptavi-
din-Sepharose (top). For
comparison, 10% of the im-
munoprecipitate was loaded
for fluorography (bottom).
(B) Turnover rates of bio-
tinylated wt and T70 CFTR.
Radioactivity incorporated
into the biotinylated CFTR
was measured with Phos-
phorImage analysis and ex-
pressed as the percentage of
the initial label. Data repre-
sent means    SEM,  n   3.
(C and D) Proteasome inhibitors delay the degradation of the biotinylated T70 CFTR. Radioactivity remaining in the biotinylated T70
CFTR was measured in pulse–chase experiments after 4 h of chase in the absence or presence of lactacystin (Lac; 10  M) or MG132
(MG; 10  M) by PhosphorImage analysis. Data are expressed as a percentage of the amount remaining for the control T70 CFTR and
represent means   SEM, n   3.The Journal of Cell Biology, Volume 153, 2001 966
B and D). The simplest interpretation of these data is that
the intrinsic structural instability of the T70 CFTR be-
comes more apparent at elevated temperature, leading to
thermodenaturation and proteolysis, whereas the compact
tertiary structures of wt CFTR are resistant to unfolding.
Discussion
A combination of transcriptional, cotranslational, and
posttranslational mechanisms contributes to the ER qual-
ity control, preventing misfolded secretory and membrane
proteins from traversing the secretory pathway (Ellgaard
et al., 1999; Wickner et al., 1999; Mori, 2000). Neverthe-
less, several examples demonstrate that the fidelity of the
ER quality control is far from perfect. Nonfunctional
polypeptides can escape ER retention, whereas mutants
with partially or fully preserved biological function are be-
ing trapped, causing severe human diseases such as CF
and alpha 1–protease inhibitor deficiency (Thomas et al.,
1995; Zielenski and Tsui, 1995; Aridor and Balch, 1999;
Schwartz and Ciechanover, 1999). Nonnative polypeptides
could also be generated in post-ER compartments as a re-
sult of unfolding upon environmental stresses or muta-
tions that compromise the native form stability (Golden-
berg, 1992; Pacifici et al., 1993; Parsell and Lindquist, 1993;
Sitte et al., 1998). Little is known about the mechanism re-
sponsible for the degradation of abnormal membrane pro-
teins from post-ER compartments.
In mammalian cells, aggregated furin, incompletely as-
sembled Golgi coronavirus E1, and mutant connexin32 are
destined for lysosomal degradation from the Golgi region
without reaching the cell surface (Armstrong et al., 1990;
Wolins et al., 1997; VanSlyke et al., 2000). A post-ER
quality control mechanism appears to be responsible for
targeting and vacuolar degradation of mutant plasma
membrane ATPase, the late Golgi protease Kex2, and a
Figure 7. Proteasome inhibitors induce the accumulation of the
polyubiquitinated T70 CFTR. (A) COS-1 cells transiently express-
ing HA-Ub, T70 CFTR, or a combination of these, were treated
with MG132 (MG; 10  M) or lactacystin (Lac; 10  M) for 3 h at
37 C. Equal amounts of cellular proteins were immunoprecipi-
tated with L12B4 and M3A7 anti-CFTR Abs and immunoblotted
with mouse monoclonal anti-HA (top) or antiubiquitin (middle)
Ab. Expression of T70 CFTR was verified by probing 10% of the
cell lysate with L12B4 anti-CFTR Ab (bottom). (B) Detection of
polyubiquitinated complex-glycosylated T70 CFTR. After the
pulse labeling (20 min) of T70 CFTR–expressing (T70) or non-
transfected (mock) BHK cells, the degradation of the core-glyco-
sylated T70 CFTR was ensured during a 2-h chase. An additional
2-h chase was performed in the presence of MG132 (MG; 10  M)
or leupeptin and pepstatin A (leu pep; 50  g/ml) (lanes 4 and 5).
CFTR–ubiquitin conjugates were isolated with sequential immu-
noprecipitation (IP) using
L12B4 and M3A7 Abs first
and then antiubiquitin Ab
(top and middle) and visual-
ized by fluorography. The
processing of the pulse-
labeled T70 CFTR pool was
monitored by visualizing 10%
of the CFTR-immunoprecipi-
tate (bottom). (C) Detection
of polyubiquitinated com-
plex-glycosylated T70 CFTR
in COS-1 cells. The experi-
mental protocols, described
for B, were performed on
transiently transfected COS-1
cells expressing T70 CFTR
and HA-Ub. Incubation with
protease inhibitors was ex-
tended to 4 h as indicated and
lactacystin (Lac) was used at
20  M. The second immuno-
precipitation was done with
anti-HA Abs.Benharouga et al. Peripheral Quality Control of CFTR 967
model protein, comprising the secretory invertase and the
NH2 terminus of the lambda repressor in Saccharomyces
cerevisiae  (Wilcox et al., 1992; Chang and Fink, 1995;
Hong et al., 1996). Aggregation of unoccupied class II ma-
jor histocompatibility complex molecules and cross-link-
ing of cell surface membrane proteins, such as the transfer-
rin receptor, can evoke preferential lysosomal targeting
and degradation (Weissman et al., 1986; Amigorena et al.,
1995). Although most of these examples illustrate that
nonnative membrane protein is targeted for lysosomal
proteolysis either before their arrival to the cell surface or
after their internalization, the complex-glycosylated trun-
cated CFTR has a distinct intracellular fate.
We presented compelling evidence indicating that the
dramatically decreased expression level and residence
time of the complex-glycosylated truncated CFTR can-
not be attributed to missorting for lysosomal degrada-
tion at the trans-Golgi or endosomal compartment. In-
stead, the truncated CFTR is targeted to the plasma
membrane with comparable efficiency to its wt counter-
part (Fig. 1). The turnover of the total and cell surface
biotinylated T70 CFTR pools was insensitive to inhibi-
tors of endolysosomal proteases. In contrast, weak bases
and cathepsin inhibitors stabilized the full-length form
and degradation intermediates of wt CFTR in trans-
fected cells as well as in epithelia, highlighting the multi-
ple role of endolysosomal proteolysis in the turnover of
wt CFTR (Figs. 2 and 3).
Several criteria were used to establish that proteasomes
are involved in the accelerated metabolism of the trun-
cated CFTR from post-Golgi compartments, including the
cell surface. First, the degradation rates of the complex-
glycosylated T70, 82, and 98 CFTR were delayed in the
presence of lactacystin, the most specific inhibitor of pro-
teasome (Fenteany et al., 1995; Fig. 4). Second, a dramatic
extension of the plasma membrane residence time of bio-
tinylated T70 CFTR was evoked by lactacystin (Fig. 6),
implying that proteasomes are indispensable in the pro-
teolysis of the truncated CFTR from the cell surface and/or
endosomal compartment. Since proteasome inhibitors had
no impact on the degradation of Tac-Lamp1, an indirect
effect of lactacystin on lysosomal proteolysis could be pre-
cluded (Fig. 5). Third, MG132 and lactacystin evoked the
accumulation of polyubiqutinated adducts of the complex-
glycosylated T70 CFTR, consistent with the notion that a
fraction of the T70 CFTR is tagged by polyubiquitin
chain(s) before degradation (Fig. 7). Finally, both MG132
and lactacystin partially restored the expression level of
complex-glycosylated T70, T82, and T98 CFTR, as well as
the plasma membrane cAMP-activated chloride conduc-
tance of T70 CFTR transfectants without facilitating the
biogenesis of the mutants (Fig. 5, D and E). Although
these observations indicate that proteasome activity is one
of the rate-limiting steps for the turnover of the full-length
complex-glycosylated T70 CFTR, proteasome inhibitors
failed to restore the mutant stability to that of the wt
Figure 8. Protease susceptibility of native wt
and T70 CFTR. After treating the cells with cy-
clohexamide (100  g/ml) for 2.5 h at 37 C to de-
plete the core-glycosylated forms, microsomes
were isolated with differential centrifugation
from BHK-21 cells stably expressing wt or T70
CFTR. Microsomes were subjected to limited
proteolysis at the indicated concentrations of
trypsin for 15 min at 4 C. The proteolytic diges-
tion pattern was probed by L12B4 anti-CFTR
Ab and ECL.
Figure 9. Thermostability
of the complex-glycosylated
wt and T70 CFTR in vivo. (A
and B) Temperature-depen-
dent turnover of the com-
plex-glycosylated T70 and wt
CFTR. Metabolic stability of
the pulse-labeled complex-
glycosylated T70 and wt
CFTR was monitored as de-
scribed in the legend to Fig.
4. Chase was conducted at
26 C, 37 C, or 40 C. (C and
D) The disappearance kinet-
ics of complex-glycosylated
T70 and wt CFTR were de-
termined by PhosphorIm-
age analysis in experiments
shown in A and B. Data are
means   SEM, n   3.The Journal of Cell Biology, Volume 153, 2001 968
CFTR. This could be explained by incomplete inhibition
of proteasome activity and/or the involvement of other,
presently unidentified proteolytic mechanisms.
The COOH-terminal tail of CFTR might confer stabil-
ity to the mature CFTR by several mechanisms or a com-
bination thereof. Deletion of the COOH terminus, com-
prising a postsynaptic density-95, disc-large, and zonula
occludens-1–binding motif (1476DTRL) that ensures the asso-
ciation of CFTR with EBP-50 (for ezrin-radixin-moesin–
binding phosphoprotein 50) both in vitro and in vivo may
facilitate lysosomal degradation by compromising endoso-
mal sorting for recycling (Hall et al., 1998; Short et al.,
1998; Moyer et al., 2000). A similar paradigm was pro-
posed for the accelerated degradation of the  2-adrenergic
receptor upon preventing its binding to EBP-50 (Cao et
al., 1999). However, this possibility appears to be unlikely,
since the steady state expression level and turnover rate of
a CFTR variant lacking the COOH-terminal 26 amino
acid residues are normal (Mickle et al., 1998; Haardt et al.,
1999). Neither can aggregation of T70 CFTR at the trans-
Golgi or at early endosomes target the mutant for lysoso-
mal degradation. Finally, the absence of the COOH-termi-
nal tail may structurally destabilize the folded CFTR,
increasing the portion of nonnative molecules that are sus-
ceptible to proteolysis.
Evidence suggests that nonnative states of soluble
polypeptides induced by mutations or thermal or chemical
denaturation can lead to accelerated degradation (Parsell
and Lindquist, 1993; Hershko and Ciechanover, 1998;
Brodsky and McCracken, 1999; Plemper and Wolf, 1999), a
paradigm that may apply to the degradation of nonnative
plasma membrane proteins, including the truncated CFTR,
as well. Based on the enhanced protease susceptibility and
the decreased in vivo thermostability of T70 CFTR (Figs. 8
and 9), we speculate that structural destabilization of the
native form is induced by disrupting interaction(s) of the
COOH terminus. Using various yeast screening assays and
site-directed mutagenesis of the Deg-1 proteolytic motif in
the MAT 2 transcription factor, it has been established
that ubiquitin-conjugating enzymes (Ubc6 and Ubc7) can
recognize hydrophobic stretches and exposed hydrophobic
surfaces on amphipathic helices (Sadis et al., 1995; Gilon et
al., 1998; Johnson et al., 1998). These or similar motifs, nor-
mally buried inside the globular domains of CFTR or in-
serted into the membrane plane, may serve as recognition
signal(s). In support of this notion, the decreased plasma
membrane residence time and impaired expression level of
the  2- and the  2A-adrenergic receptors were also attrib-
uted to structural destabilization (Gether et al., 1997; Wil-
son and Limbird, 2000). However, the mechanism respon-
sible for the downregulation of these G protein–coupled
receptors, which could be partially rescued with ligand sta-
bilization, has remained obscure.
A key question that remains to be resolved is whether
ubiquitination is a prerequisite for proteasome-dependent
degradation of the mutant CFTR from the cell surface or
endosomal compartment. Several tyrosine kinase and G
protein–coupled receptors have been observed to undergo
ligand-induced ubiquitination and downregulation via ly-
sosomal and/or proteasomal degradation (Bonifacino and
Weismann, 1998; Hershko and Ciechanover, 1998; Hicke,
1999; Strous and Govers, 1999). Ubiquitination also ap-
pears to be necessary and sufficient to induce the internal-
ization and downregulation of plasma membrane recep-
tors and transporters (e.g., FUR4, GAP1, STE2, STE3,
and STE6) via vacuolar proteolysis in yeast (Hicke, 1999).
The constitutive downregulation of the epithelial sodium
channel (ENaC), in association with the Nedd4 ubiquitin-
ligase, was proposed to follow a similar degradation route,
in contrast to the unassembled subunits of the channel,
which were degraded by a proteasome-dependent mecha-
nism at the ER (Staub et al., 1997).
Since both covalent and noncovalent attachment of
ubiquitins can serve as a degradation signal of plasma
membrane proteins via internalization (Govers et al.,
1999; Shih et al., 2000), one possible scenario is that aug-
mented ubiquitination of CFTR, or an associated protein,
facilitates the internalization of the mutant. On the other
hand, in light of multiple tyrosine- and dileucine-based en-
docytic signals in CFTR, ubiquitin attachment may not be
a prerequisite for endocytosis (Lukacs et al., 1997; Prince
et al., 1999; Hu et al., 2001). Consistent with the dispens-
able nature of ubiquitination, downregulation of the
 2-adrenergic and mutant m2-muscarinic receptors can
proceed without endocytosis, presumably by direct associ-
ation with proteasome and/or other, presently unidentified
proteases (Jockers et al., 1999; Wilson and Limbird, 2000).
The recognition that both 26S proteasome and P700 sub-
unit are able to degrade nonnative polypeptides lack-
ing polyubiquitin conjugates supports the notion that a
ubiquitin-independent degradation mechanism cannot be
ruled out (Murakami, 1992; Braun et al., 1999; Sheaff et
al., 2000; Strickland et al., 2000). Importantly, these degra-
dation pathways are not mutually exclusive and may func-
tion in parallel.
Since the retrograde translocation of the T70 CFTR via
the translocon is unlikely to occur in post-Golgi compart-
ments (Xiong et al., 1999), the coordinated action of multi-
ple proteolytic systems is invoked to resolve the topologi-
cal problem of disposing transmembrane segments and
exofacial loops of the T70 CFTR. Degradation appears to
be initiated by the unfolding of cytosolic domains in a pro-
teasome-dependent manner. The biochemical as well as
functional rescue of cell surface resident T70, but not wt
CFTR (data not shown), by proteasome inhibitors sub-
stantiate this hypothesis. Whereas the initial cleavage of
the mature wt CFTR, as opposed to mutant, relies on the
activity of lysosmal proteases, subsequent degradation of
wt and T70 CFTR converges in endolysosomes, demon-
strated by their overlapping proteolytic fragmentation pat-
tern in the presence of cathepsin inhibitors (Fig. 3 B).
Although the truncated CFTR is one of the first mutant
plasma membrane proteins subjected to sequential protea-
somal and lysosomal breakdown, the coordinated action
of these proteolytic systems is not without precedent. Al-
though both lysosomes and proteasomes are involved in
the constitutive and ligand-induced disposal of con-
nexin43, the renal Na/Pi cotransporter, and the PDGF  
receptor, respectively (Mori et al., 1995; Laing et al., 1997;
Pfister et al., 1998), the recognition mechanism of these
substrates by the proteasome remains unknown. Consider-
ing that deletion of the COOH-terminal tail appears to de-
stabilize CFTR structurally, we propose that the ubiquitin-
proteasome pathway may play a role in the recognitionBenharouga et al. Peripheral Quality Control of CFTR 969
and elimination of not only the T70 CFTR, but also other
nonnative or partially unfolded plasma membrane pro-
teins.
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